Abiopharma

🔍 Roman Michael F (Executive)

Company: ABBOTT LABORATORIES (ABT)

Report Date: 2025-12-31

Detailed Transactions and Holdings:

• Acquired 301 shares of Stock Equivalent Units (Derivative)
  Date: 2025-12-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 5,882.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F2

Footnotes:

• F1: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.
• F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.